VTRS

Viatris Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
$13.91
+0.08 (+0.58%)
Mkt Cap: 16.02B
Key Metrics
MetricValue
P/E RatioN/A
EV/EBITDAN/A
ROEN/A
Gross MarginN/A
Revenue GrowthN/A
FCF Yield13.3%
Dividend YieldN/A
Market Cap16.02B
Volume6.44M
Recent News
Viatris to Report First Quarter 2026 Financial Results on May 7, 2026
prnewswire.com · 2026-04-13
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
prnewswire.com · 2026-04-10
Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative Medicines Transcript
seekingalpha.com · 2026-03-25
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
prnewswire.com · 2026-03-23
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030
prnewswire.com · 2026-03-19
ISCV vs. VBR: Which Small Cap Value Approach is Right for Investors?
fool.com · 2026-03-17

Unlock the Full Deep Scan

9 AI agents analyze VTRS across earnings, insider flow, macro conditions, corporate strategy, market microstructure, and price action.

Sign Up Free →